No Data
Chenxin Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Chenxin Pharmaceutical Co., Ltd.
Cisen Pharmaceutical (603367.SH): net income of 0.27 billion yuan in the first half of the year, a year-on-year increase of 2.33%.
On August 27th, Gelonhui, Cisen Pharmaceutical (603367.SH) announced its semi-annual report. In the first half of 2024, the company achieved a revenue of 2.071 billion yuan, a decrease of 6.72% compared to the same period last year. The company's total profit amounted to 0.292 billion yuan, an increase of 0.34% compared to the same period last year. The net income attributable to the owner of the parent company was 0.27 billion yuan, an increase of 2.33% compared to the same period last year. A cash dividend of 2.20 yuan per 10 shares was distributed to all shareholders.
Cisen Pharmaceutical (603367.SH) plans to distribute a dividend of 0.436 yuan per share on June 27th.
Cisen Pharmaceutical (603367.SH) announced that it plans to distribute annual equity dividends in 2023: A shares will receive cash dividends of... per share.
Is Cisen Pharmaceutical (SHSE:603367) Using Too Much Debt?
Chenxin Pharmaceutical (603367.SH): R&D investment in 2023 accounts for more than 8% of revenue
Gelonghui, May 9丨Chen Xin Pharmaceutical (603367.SH) said at the performance briefing that Chen Xin Pharmaceutical adheres to the development concept of “introducing innovation, honesty and trustworthiness” and has always used scientific and technological innovation as the driving force for sustainable development. In 2023, R&D investment accounted for more than 8% of revenue, which strongly supported the company's transformation, upgrading and sustainable development. At the same time, the company adheres to the combination of independent innovation and cooperative innovation. On the basis of independent research and development, the company attaches great importance to various collaborations. It has successively cooperated with Georgia State University in the United States, Liverpool University in the UK, Peking University, the Academy of Military Medical Sciences, China Pharmaceutical University, and Shandong
No Data
